M. Anghelescu *, A. Streinu-Cercel *
* Prof. dr. Mircea Angelescu, dr. Adrian Streinu-Cercel, Institutul de boli Infecțioase Prof. dr. Matei Balș, București
Abstract
Empirical therapy with Amoksiklav 2X® in respiratory infections
Amoksiklav 2X representes nowaday the first choice empirical treatment in respiratory tract infections such as: community-acquired pneumonia, infectious exacerbations of chronic bronchitis, acute otitis media, acute and chronic sinusitis and other bacterial respiratory tract infections. The pathogens with the highest frecquency causing these diseases are Streptococcus pneumoniae, Haemophilus influenza and Moraxella catarrhalis, germs with numerous resistant strains to penicillin G, V and aminopenicillin.